MedTrace Logo

CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility

NCT03986463 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2021-02-18

No results posted yet for this study

Summary

This is a prospective observation study in patients with non-small cell lung cancer (NSCLC) starting either cytotoxic chemotherapy or radiation therapy. It will assess changes in circulating tumor DNA (ctDNA) in the days following the initiation of treatment, as well as longitudinal monitoring, to assess the dynamics and value of ctDNA in stage III-IV NSCLC.

Conditions

  • Lung Neoplasms
  • Lung Cancer
  • Neoplasm of Lung
  • Non Small Cell Lung Cancer

Interventions

OTHER

Circulating tumour DNA (ctDNA)

Circulating tumour DNA (ctDNA) will be isolated from blood samples

Sponsors & Collaborators

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03986463 on ClinicalTrials.gov